Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo- and Ezetimibe-controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10-year Framingham Risk Score of 10% or Less

NCT01375777 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01375777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01375777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo- and Ezetimibe-controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10-year Framingham Risk Score of 10% or Less
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2011
Completion date
March 2, 2012
Enrollment
411 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia